Lantheus Holdings (LNTH) Payments To Acquisition Of In Process Research And Development — Quarterly & Annual

Screener

Payments To Acquisition Of In Process Research And Development at other companies

ExelixisEXEL

$2.5M+233%

BioLife SolutionsBLFS

$2.56M—

Tandem Diabetes CareTNDM

$0—

ImmunomeIMNM

$9.01M+44.3%

Taysha Gene Therapies, Inc.TSHA

$3M+694%

Eli LillyLLY

$3.28B+2,967%

Other financials

Income statement

Revenue$388.2M+2.7%

Gross profit$241.9M+0.4%

Operating income$100.2M+13.9%

Net income$75.0M-4.7%

EPS (diluted)$1.11-0.9%

Balance sheet

Cash & equivalents$595.0M-14.7%

Total debt$626.8M+1.5%

Total equity$1.3B+12.4%

Total assets$2.4B+14.1%

Cash flow

Operating cash flow$92.2M+5.9%

CapEx$2.3M-70.7%

Free cash flow$89.9M+13.5%

Valuation

Market cap$6.59B+72.9%

Enterprise value$6.62B+77.4%

P/E23.9×+10.5×

P/S4.2×+1.7×

Profitability

Gross margin60.1%-3.6pp

Operating margin19.4%-9.4pp

Net margin17.7%-0.9pp

FCF margin24.9%-6.6pp

Returns & leverage

Return on equity22.2%-3.6pp

Debt / equity0.5×-0.1×

Current ratio3.1×-1.2×

Where this comes from

Reported directly by Lantheus Holdings in its filing.

Tagged under the XBRL concept lnth:PaymentsToAcquisitionOfInProcessResearchAndDevelopment.

The source filing: Lantheus Holdings’s 10-K, filed February 26, 2026. Open the filing →

Filed: Feb 26, 2026, 8:00 AM EST
Fiscal year: FY2025
Accession: 0001193125-26-073498

FAQ

What is Lantheus Holdings's payments to acquisition of in process research and development?: Lantheus Holdings (LNTH) reported payments to acquisition of in process research and development of $1.35M in Q4 2025.
What does payments to acquisition of in process research and development mean?: Payments To Acquisition Of In Process Research And Development as reported by Lantheus Holdings, Inc.

Ask your AI about Lantheus Holdings's payments to acquisition of in process research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk